+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Handbook of Pharmacogenomics and Stratified Medicine

  • Book

  • October 2018
  • Elsevier Science and Technology
  • ID: 2736057
Handbook of Pharmacogenomics and Stratified Medicine is a comprehensive resource to understand this rapidly advancing field aiming to deliver the right drug at the right dose to the right patient at the right time. It is designed to provide a detailed, but accessible review of the entire field from basic principles to applications in various diseases. The chapters are written by international experts to allow readers from a wide variety of backgrounds, clinical and non-clinical (basic geneticists, pharmacologists, clinicians, trialists, industry personnel, ethicists) to understand the principles underpinning the progress in this area, the successes, failures and the challenges ahead. To be accessible to the widest range of readers, the clinical application section introduces the disease process, existing therapies, followed by pharmacogenomics and stratified medicine details.

Medicine is the cornerstone of modern therapeutics prescribed on the basis that its benefit should outweigh its risk. It is well known that people respond differently to medications and in many cases the risk-benefit ratio for a particular drug may be a gray area. The last decade has seen a revolution in genomics both in terms of technological innovation and discovering genetic markers associated with disease. In parallel there has been steady progress in trying to make medicines safer and tailored to the individual. This has occurred across the whole spectrum of medicine, some more than others. In addition there is burgeoning interest from the pharmaceutical industry to leverage pharmacogenomics for more effective and efficient clinical drug development.

Table of Contents

I. Introduction II. Basic genetics III. Experimental and discovery platforms IV. Statistics, bioinformatics, and databases V. Clinical trials VI. Fundamental pharmacogenomics VII. Applications in therapeutics VIII. Implementation and regulatory IX. Global perspective

Authors

Sandosh Padmanabhan Professor of Cardiovascular Genomics and Therapeutics, BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK. Dr. Sandosh Padmanabhan MD, PhD, FRCP, FAHA, FBHS, FBPhS is a Professor and Physician at the Institute of Cardiovascular and Medical Sciences, University of Glasgow. Dr. Padmanabhan completed his MBBS and MD at JIPMER, Pondicherry, India and was awarded the Gold Medal for MD General Medicine in 1995. His PhD thesis (1999-2003) on G-protein signaling in hypertension was awarded the Bellahouston Medal by the University of Glasgow in 2004, and he received the Austin Doyle Award from the International Society of Hypertension in 2004. Dr. Padmanabhan's pharmacogenetic genome-wide linkage study led to a BHF Intermediate Fellowship (2006-2009), and he also led a genome wide association analysis of hypertension between 2008 and 2010, resulting in the discovery of a new gene and pathway for hypertension. Dr. Padmanabhan was a visiting fellow to the Broad Institute of Harvard and MIT (2010-2012). Currently, he is a Fellow of the Royal College of Physicians, the British Hypertension Society, and the American Heart Association. His active research areas span the genetics of cardiovascular traits, pharmacogenomics and stratified medicine, and hypertension epidemiology.